Health Minister Mark Butler confirmed on 16 July 2026 that three multiple sclerosis drugs — Ocrevus, Kesimpta and Lemtrada — will stay on the Pharmaceutical Benefits Scheme, the government program that makes essential medicines affordable. Patients with MS and their doctors had been waiting weeks to hear whether the drugs would stay subsidised.

The decision is only temporary. An independent expert group called the Pharmaceutical Benefits Advisory Committee, or PBAC, advises the government on which drugs should be on the PBS. PBAC has called for a quick review of MS drug use to be finished before the end of 2026. A final decision will come after that.

The trouble started in late 2025, when a new MS drug called Briumvi was added to the PBS at a lower price than the drugs already on the list. The PBS uses a system called reference pricing to keep costs down. Here's how it works: when several drugs treat the same condition, the government links the price it pays for all of them to the cheapest one. So when Briumvi arrived at a lower price, it automatically pulled down the price the government would pay for two established drugs — Kesimpta (made by Novartis) and Ocrevus (made by Roche).

Roche's general manager, Dr Nic Horridge, said the price cut "would make it impossible to keep Ocrevus on the PBS." That's a familiar line from drug companies when this pricing system bites: they say they'll withdraw their drug rather than accept the lower price, and frame it as a commercial necessity. Whether that's a real deal-breaker or just a bargaining move is what the PBAC review will need to figure out before the end of the year.

The money at stake is significant. Under the PBS, a monthly dose of Kesimpta costs the government AU$2,231. A course of Ocrevus costs AU$16,500. In the United States, Kesimpta can cost more than US$10,000 per month. Australians pay far less because the government buys drugs in bulk on behalf of the whole country — it uses the buying power of 26 million people to negotiate lower prices. That's the whole point of the PBS.

Reference pricing is meant to pass savings on to taxpayers: a cheaper drug arrives, prices across the group fall, and the government's bill shrinks. But if the makers of the established drugs decide the new price is too low, the system can backfire. Instead of cheaper drugs, you get fewer drugs on the scheme. Patients then have to switch treatments or pay the full price themselves.

ABC News reported on 8 July 2026 that the dispute could result in Ocrevus and Kesimpta being pulled from the PBS, potentially leaving MS patients with large out-of-pocket costs. MS Australia acknowledged the coverage on its Facebook account the next day, a sign patient groups were watching closely.

Lemtrada's inclusion in Butler's announcement is worth noting. Lemtrada wasn't directly affected by the Briumvi price change, and its appearance alongside Ocrevus and Kesimpta suggests the review will look at the whole range of MS drugs, not just the ones caught up in the Briumvi pricing flow-on.

For the roughly 33,000 Australians living with MS, the immediate pressure is off. The drugs remain available at PBS-subsidised prices. But the review timeline is tight, and the pricing system that caused the problem hasn't changed. A cheaper drug entering the market will keep pulling prices down for every other drug in the group. The review has to work out whether the government can keep saving money this way while making sure patients who need a specific drug can still get it.

Butler has essentially bought time. The argument that these drugs have real clinical benefit is solid: they reduce relapse rates and slow the progression of MS, and switching patients off a treatment that's working carries genuine medical risk. But "clinical benefit" doesn't solve a pricing dispute. By year's end, PBAC will need to have found a way to make the pricing arithmetic work alongside the medical case for keeping these drugs available — or Butler will be back explaining why a system designed to save money has instead left patients with fewer options.

The broader context here is that the government clearly wants Briumvi's cheaper price to flow through to lower costs across all MS drugs, without any manufacturer walking away. Whether the drug companies and the PBAC can agree on a price that achieves both of those things is the only question that matters between now and December.